<div id="readability-page-1"><div><p>On January 30, 2026, Amgen Inc. entered into a Termination Agreement with Kyowa Kirin Co. Ltd. pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the &#34;License and Collaboration Agreement&#34;). The termination of the License and Collaboration Agreement will become effective upon receipt of regulatory approval.</p><p>The foregoing description of the Termination Agreement and the termination of the License and collaboration agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference.</p></div></div>

<p>Amgen Inc. has entered into a Termination Agreement with Kyowa Kirin Co., Ltd. to terminate their License and Collaboration Agreement from June 1, 2021. This termination will take effect upon receiving regulatory approval. The details of the Termination Agreement are outlined in Exhibit 10.1, which is referenced for completeness.</p>

marketscreener

Kyowa Kirin Co., Ltd.

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

Amgen

Amgen Inc. Enters into A Termination Agreement with Kyowa Kirin Co., Ltd